CA
NZ
UK
US
AU
IND
Last update at 2025-05-07T16:31:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Knight to Participate in Crescita Rights Offering
Tue 20 Feb 18, 11:00 AMKnight participera à l'offre de droits dans Crescita
Tue 20 Feb 18, 11:00 AMKnight Increases Ownership in Crescita
Tue 10 Oct 17, 12:00 PMKnight accroît sa participation dans Crescita
Tue 10 Oct 17, 12:00 PMKnight Supports Crescita Trajectory
Mon 14 Aug 17, 12:35 PMKnight appuie le parcours de Crescita
Mon 14 Aug 17, 12:35 PMThérapeutique Knight inc. : INTEGA en pleine Crescita (croissance en italien)
Thu 01 Sep 16, 01:24 PMKnight Therapeutics Inc.: INTEGA Skin Primed for Crescita (Italian for Growth)
Thu 01 Sep 16, 01:23 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 0.40M | -1.00900M | 0.52M | 3.18M | 0.65M |
| Minority interest | - | - | - | - | - |
| Net income | 0.86M | -1.10500M | 0.04M | 1.85M | 2.40M |
| Selling general administrative | 10.57M | 8.55M | 7.13M | 8.46M | 10.06M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 13.18M | 10.01M | 11.27M | 16.54M | 11.09M |
| Reconciled depreciation | 1.47M | 1.38M | 1.49M | 1.73M | 1.15M |
| Ebit | 0.73M | -0.52900M | 2.51M | 3.97M | 1.23M |
| Ebitda | 2.20M | 0.85M | 4.00M | 5.70M | 2.37M |
| Depreciation and amortization | 1.47M | 1.38M | 1.49M | 1.73M | 1.15M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 0.73M | -0.52900M | 2.51M | 3.97M | -0.03700M |
| Other operating expenses | 23.00M | 17.49M | 14.09M | 17.37M | 16.66M |
| Interest expense | 0.16M | 0.24M | 0.25M | 0.68M | 0.60M |
| Tax provision | -0.45800M | 0.10M | 0.48M | 1.32M | -1.77300M |
| Interest income | 0.26M | 0.24M | 0.29M | 0.11M | 0.07M |
| Net interest income | 0.10M | -0.05400M | 0.04M | -0.40300M | -0.49300M |
| Extraordinary items | - | - | - | 0.00000M | -0.02600M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.45800M | 0.10M | 0.48M | 1.32M | -1.77300M |
| Total revenue | 23.52M | 16.77M | 15.64M | 22.34M | 16.63M |
| Total operating expenses | 12.65M | 10.73M | 9.72M | 11.57M | 11.13M |
| Cost of revenue | 10.34M | 6.75M | 4.37M | 5.80M | 5.54M |
| Total other income expense net | -0.32800M | -0.48000M | -1.99400M | -0.79000M | 0.69M |
| Discontinued operations | - | - | - | - | -0.02600M |
| Net income from continuing ops | 0.86M | -1.10500M | 0.04M | 1.85M | 2.42M |
| Net income applicable to common shares | 0.86M | -1.10500M | 0.04M | 1.85M | 2.40M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 24.60M | 28.48M | 28.92M | 26.83M | 26.84M |
| Intangible assets | 1.99M | 2.87M | 3.74M | 4.61M | 7.57M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.20M | 0.39M | 0.62M | 0.30M | 0.29M |
| Total liab | 5.78M | 7.39M | 8.40M | 5.70M | 5.73M |
| Total stockholder equity | 18.82M | 21.10M | 20.53M | 21.13M | 21.11M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.10M | 5.65M | 5.38M | 4.32M | 0.05M |
| Common stock | 54.34M | 56.30M | 58.08M | 58.18M | 58.42M |
| Capital stock | 54.34M | 56.30M | 58.08M | 58.18M | 58.42M |
| Retained earnings | -42.59900M | -40.61300M | -41.47500M | -40.37000M | -40.40700M |
| Other liab | - | 0.12M | 0.15M | 0.15M | 0.20M |
| Good will | - | - | - | - | - |
| Other assets | - | 0.46M | 2.18M | 2.03M | 2.16M |
| Cash | 9.38M | 8.24M | 11.33M | 14.28M | 9.27M |
| Cash and equivalents | - | 8.24M | 11.33M | 14.28M | 9.27M |
| Total current liabilities | 4.86M | 6.06M | 6.72M | 4.62M | 4.34M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -8.13100M | -6.62500M | -8.46300M | -13.05100M | -7.72000M |
| Short term debt | 0.44M | 0.41M | 1.34M | 0.30M | 0.36M |
| Short long term debt | - | - | 0.98M | - | - |
| Short long term debt total | 1.25M | 1.61M | 2.87M | 1.23M | 1.55M |
| Other stockholder equity | 5.96M | 4.27M | 2.77M | 2.27M | 1.95M |
| Property plant equipment | - | 2.31M | 2.58M | 0.79M | 1.18M |
| Total current assets | 18.49M | 20.52M | 20.09M | 19.40M | 15.92M |
| Long term investments | 0.36M | 0.34M | 0.34M | - | - |
| Net tangible assets | - | 18.23M | 16.79M | 16.52M | 13.54M |
| Short term investments | 0.00300M | - | - | - | 0.06M |
| Net receivables | 2.77M | 6.24M | 3.75M | 1.36M | 2.58M |
| Long term debt | - | - | 0.00000M | 0.93M | 0.90M |
| Inventory | 6.12M | 5.65M | 4.39M | 3.46M | 3.78M |
| Accounts payable | 4.33M | 5.59M | 5.33M | 4.27M | 3.94M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 1.12M | 1.13M | 1.15M | 1.05M | 1.15M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 58.18M | 58.42M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.99M | 2.00M | 2.18M | 2.03M | 1.58M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 6.11M | 7.97M | 8.83M | 7.43M | 10.91M |
| Capital lease obligations | 1.25M | 1.61M | 1.89M | 0.30M | 0.65M |
| Long term debt total | - | 1.21M | 1.52M | 0.93M | 1.19M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.29000M | -0.84600M | -0.05900M | -0.21500M | -0.14400M |
| Change to liabilities | 0.23M | 0.99M | 0.33M | 0.16M | 0.51M |
| Total cashflows from investing activities | -0.29000M | -0.84600M | -0.05900M | -0.21500M | -0.14400M |
| Net borrowings | -1.37300M | -0.34900M | -0.35800M | -3.88700M | -3.88700M |
| Total cash from financing activities | -1.84600M | -0.50000M | -0.47600M | -4.39400M | 3.19M |
| Change to operating activities | 0.27M | -0.26700M | 0.04M | 0.09M | 0.10M |
| Net income | 0.86M | -1.10500M | 0.04M | 1.85M | 2.40M |
| Change in cash | -3.09300M | -2.95000M | 5.01M | 0.68M | 1.59M |
| Begin period cash flow | 11.33M | 14.28M | 9.27M | 8.59M | 7.00M |
| End period cash flow | 8.24M | 11.33M | 14.28M | 9.27M | 8.59M |
| Total cash from operating activities | -1.02000M | -1.59700M | 5.61M | 5.31M | -1.47800M |
| Issuance of capital stock | - | - | - | 0.00000M | 3.52M |
| Depreciation | 1.47M | 1.38M | 1.49M | 1.73M | 1.15M |
| Other cashflows from investing activities | -0.06100M | -0.50000M | -0.50000M | -0.50000M | -0.50000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -1.78000M | -1.37500M | -0.04100M | -1.33800M | 0.32M |
| Change to account receivables | -2.57200M | -1.04200M | 1.25M | 2.81M | -3.88300M |
| Sale purchase of stock | -0.42900M | -0.10100M | -0.06800M | -0.25700M | 3.53M |
| Other cashflows from financing activities | -0.04400M | -0.05000M | -0.05000M | -0.25000M | -0.33400M |
| Change to netincome | 0.36M | -0.40500M | 2.50M | -0.00400M | -2.06600M |
| Capital expenditures | 0.23M | 0.35M | 0.06M | 0.21M | 0.14M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -3.71500M | -1.46600M | 1.58M | 1.73M | -2.95400M |
| Stock based compensation | 0.22M | 0.27M | 0.15M | 0.29M | 0.34M |
| Other non cash items | 0.60M | -0.77300M | 1.86M | -1.61600M | -0.63500M |
| Free cash flow | -1.24900M | -1.94300M | 5.55M | 5.09M | -1.62200M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CTX Crescita Therapeutics Inc |
-0.02 3.45% | 0.56 | - | - | 0.67 | 0.65 | 0.19 | 2.27 |
| BHC Bausch Health Companies Inc |
0.20 3.07% | 6.71 | - | 2.23 | 0.50 | 18.74 | 2.56 | 9.13 |
| CURA Curaleaf Holdings Inc. |
0.03 2.52% | 1.22 | - | 138.89 | 1.62 | 1.66 | 1.73 | 10.18 |
| TLRY Tilray Inc |
0.02 3.39% | 0.61 | - | 1000.00 | 2.17 | 0.36 | 1.69 | -2.299 |
| CRON Cronos Group Inc |
0.24 9.38% | 2.80 | - | - | 10.18 | 0.70 | 0.02 | -1.9458 |
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers and DuraPeel that supports the development of patented formulations that can deliver actives into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; a development and commercialization license agreement with Taro Pharmaceuticals Inc.; and a distribution and promotion agreement with FILLMED. Crescita Therapeutics Inc. was founded in 2016 and is headquartered in Laval, Canada.
2805 Place Louis-R Renaud, Laval, QC, Canada, H7V 0A3
| Name | Title | Year Born |
|---|---|---|
| Mr. Serge Verreault B.A., M.B.A. | Pres & CEO | NA |
| Mr. Jose DaRocha C.A., CPA | Chief Financial Officer | NA |
| Mr. Francois Lafortune | Exec. VP & GM | NA |
| Dominic King-Smith | VP of Bus. Devel. | NA |
| Mr. Serge Verreault B.A., M.B.A. | President, CEO & Director | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...